PHASE-I EVALUATION OF PIPERAZINEDIONE IN PATIENTS WITH ADVANCED CANCER

1 January 1979

journal article
research article

Vol. 63 (1) , 73-76

Abstract

The effects of i.v. administered piperazinedione were studied in 28 evaluable adult and 8 evaluable pediatric patients with advanced cancer. Piperazinedione produced predictable myelosuppression of moderate degree at dosages of 3-3.5 mg/m2 per day .times. 5 days by i.v. injection. When given in this manner, nausea and vomiting did not occur. Single i.v. doses of 10-15 mg/m2 produced mild-to-moderate nausea and vomiting and mild myelosuppression. Thrombocytopenia was more severe than leukopenia in both schedules. The drug produced comparable dose-related effects in adults and children. Although no therapeutic response was observed in the adults, a partial remission of 6-mo. duration was seen in 1 child with Hodgkin''s disease.

This publication has 3 references indexed in Scilit:

PHASE-II TRIAL OF PIPERAZINEDIONE IN HODGKINS-DISEASE, NON-HODGKINS LYMPHOMA, AND MULTIPLE-MYELOMA - SOUTHWEST ONCOLOGY GROUP STUDY
1977
STUDIES WITH 2,5-PIPERAZINEDIONE, 3,6-BIS(5-CHLORO-2-PIPERIDYL)-, DIHYDROCHLORIDE .3. BIOCHEMICAL AND THERAPEUTIC EFFECTS IN L1210 LEUKEMIAS SENSITIVE AND RESISTANT TO ALKYLATING-AGENTS - COMPARISON WITH MELPHALAN, CYCLOPHOSPHAMIDE, AND BCNU
1976
Analogs of 1-β-d-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies
Biochemical Pharmacology, 1967